- Home
- PDM vs DBVT Comparison
PDM vs DBVT Comparison
Compare PDM & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PDM | DBVT |
|---|---|---|
| Founded | 1997 | 2002 |
| Country | United States | France |
| Employees | N/A | 90 |
| Industry | Building operators | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.1B |
| IPO Year | 1997 | 2014 |
Fundamental Metrics
Financial Performance| Metric | PDM | DBVT |
|---|---|---|
| Price | $8.22 | $18.23 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 7 |
| Target Price | $9.00 | ★ $32.04 |
| AVG Volume (30 Days) | ★ 981.6K | 146.9K |
| Earning Date | 04-30-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 10.26 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $564,994,000.00 | $5,636,000.00 |
| Revenue This Year | $4.21 | $35.04 |
| Revenue Next Year | $1.29 | $2,360.78 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 35.77 |
| 52 Week Low | $6.32 | $7.53 |
| 52 Week High | $9.19 | $26.19 |
Technical Indicators
Market Signals| Indicator | PDM | DBVT |
|---|---|---|
| Relative Strength Index (RSI) | 57.29 | 35.99 |
| Support Level | $8.16 | $16.49 |
| Resistance Level | $8.78 | $21.61 |
| Average True Range (ATR) | 0.22 | 0.76 |
| MACD | -0.06 | -0.16 |
| Stochastic Oscillator | 47.94 | 3.15 |
Price Performance
Historical ComparisonAbout PDM Piedmont Office Realty Trust Inc.
Piedmont Realty Trust Inc is a fully integrated, self-managed real estate investment company focused on delivering an exceptional office environment. As an owner, manager, developer and operator of 16 MM SF of Class A properties across U.S. Sunbelt markets, Piedmont Realty Trust is known for its hospitality-driven approach and commitment to transforming buildings into Piedmont PLACEs that enhance each client's workplace experience.
About DBVT DBV Technologies S.A.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.